These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 16294031)

  • 21. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.
    Hoda MA; Mohamed A; Ghanim B; Filipits M; Hegedus B; Tamura M; Berta J; Kubista B; Dome B; Grusch M; Setinek U; Micksche M; Klepetko W; Berger W
    J Thorac Oncol; 2011 May; 6(5):852-63. PubMed ID: 21358348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma.
    Kitamura A; Matsushita K; Takiguchi Y; Shimada H; Tada Y; Yamanaka M; Hiroshima K; Tagawa M; Tomonaga T; Matsubara H; Inoue M; Hasegawa M; Sato Y; Levens D; Tatsumi K; Nomura F
    Cancer Sci; 2011 Jul; 102(7):1366-73. PubMed ID: 21435101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of GADD34 in modulation of cisplatin cytotoxicity.
    Fishel ML; Rabik CA; Bleibel WK; Li X; Moschel RC; Dolan ME
    Biochem Pharmacol; 2006 Jan; 71(3):239-47. PubMed ID: 16325149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer.
    Toyoizumi T; Mick R; Abbas AE; Kang EH; Kaiser LR; Molnar-Kimber KL
    Hum Gene Ther; 1999 Dec; 10(18):3013-29. PubMed ID: 10609661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase.
    Stanziale SF; Petrowsky H; Joe JK; Roberts GD; Zager JS; Gusani NJ; Ben-Porat L; Gonen M; Fong Y
    Surgery; 2002 Aug; 132(2):353-9. PubMed ID: 12219034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma.
    Ozvaran MK; Cao XX; Miller SD; Monia BA; Hong WK; Smythe WR
    Mol Cancer Ther; 2004 May; 3(5):545-50. PubMed ID: 15141012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: a potential target to increase anticancer activity.
    Stanziale SF; Petrowsky H; Adusumilli PS; Ben-Porat L; Gonen M; Fong Y
    Clin Cancer Res; 2004 May; 10(9):3225-32. PubMed ID: 15131064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.
    Iwahori K; Serada S; Fujimoto M; Ripley B; Nomura S; Mizuguchi H; Shimada K; Takahashi T; Kawase I; Kishimoto T; Naka T
    Int J Cancer; 2013 Jan; 132(2):459-71. PubMed ID: 22532243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma.
    Nakashima H; Nguyen T; Kasai K; Passaro C; Ito H; Goins WF; Shaikh I; Erdelyi R; Nishihara R; Nakano I; Reardon DA; Anderson AC; Kuchroo V; Chiocca EA
    Clin Cancer Res; 2018 Jun; 24(11):2574-2584. PubMed ID: 29511029
    [No Abstract]   [Full Text] [Related]  

  • 30. What's the place of immunotherapy in malignant mesothelioma treatments?
    Grégoire M
    Cell Adh Migr; 2010; 4(1):153-61. PubMed ID: 20179421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncolytic herpes simplex virus-1 mutant expressing green fluorescent protein can detect and treat peritoneal cancer.
    Stanziale SF; Stiles BM; Bhargava A; Kerns SA; Kalakonda N; Fong Y
    Hum Gene Ther; 2004 Jun; 15(6):609-18. PubMed ID: 15212719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
    Gauvrit A; Brandler S; Sapede-Peroz C; Boisgerault N; Tangy F; Gregoire M
    Cancer Res; 2008 Jun; 68(12):4882-92. PubMed ID: 18559536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
    Jänne PA; Taffaro ML; Salgia R; Johnson BE
    Cancer Res; 2002 Sep; 62(18):5242-7. PubMed ID: 12234991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer.
    Stiles BM; Bhargava A; Adusumilli PS; Stanziale SF; Kim TH; Rusch VW; Fong Y
    Surgery; 2003 Aug; 134(2):357-64. PubMed ID: 12947341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
    Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncolytic vaccinia virus as an adjuvant treatment to cytoreductive surgery for malignant peritoneal mesothelioma.
    Acuna SA; Ottolino-Perry K; Çako B; Tang N; Angarita FA; McCart JA
    Ann Surg Oncol; 2014 Jul; 21(7):2259-66. PubMed ID: 24719018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Oncolytic Caprine Herpesvirus 1 (CpHV-1) Induces Apoptosis and Synergizes with Cisplatin in Mesothelioma Cell Lines: A New Potential Virotherapy Approach.
    Forte IM; Indovina P; Montagnaro S; Costa A; Iannuzzi CA; Capone F; Camerlingo R; Malfitano AM; Pentimalli F; Ferrara G; Quintiliani M; Portella G; Giordano A; Ciarcia R
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro anti-mesothelioma activity of cisplatin-gemcitabine combinations: evidence for sequence-dependent effects.
    Zanellato I; Boidi CD; Lingua G; Betta PG; Orecchia S; Monti E; Osella D
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):265-73. PubMed ID: 20369238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer.
    Gholami S; Chen CH; Gao S; Lou E; Fujisawa S; Carson J; Nnoli JE; Chou TC; Bromberg J; Fong Y
    Cancer Gene Ther; 2014 Jul; 21(7):283-9. PubMed ID: 24924199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.